174 related articles for article (PubMed ID: 10760357)
1. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.
Shekhar A; Keim SR
Neuropharmacology; 2000 Apr; 39(7):1139-46. PubMed ID: 10760357
[TBL] [Abstract][Full Text] [Related]
2. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions.
Shekhar A; Keim SR; Simon JR; McBride WJ
Pharmacol Biochem Behav; 1996 Oct; 55(2):249-56. PubMed ID: 8951961
[TBL] [Abstract][Full Text] [Related]
3. Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.
Johnson PL; Fitz SD; Engleman EA; Svensson KA; Schkeryantz JM; Shekhar A
J Psychopharmacol; 2013 Feb; 27(2):152-61. PubMed ID: 22914798
[TBL] [Abstract][Full Text] [Related]
4. Panic-prone state induced in rats with GABA dysfunction in the dorsomedial hypothalamus is mediated by NMDA receptors.
Johnson PL; Shekhar A
J Neurosci; 2006 Jun; 26(26):7093-104. PubMed ID: 16807338
[TBL] [Abstract][Full Text] [Related]
5. The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder.
Shekhar A; Keim SR
J Neurosci; 1997 Dec; 17(24):9726-35. PubMed ID: 9391025
[TBL] [Abstract][Full Text] [Related]
6. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Monn JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):175-80. PubMed ID: 9750002
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
8. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
9. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
11. A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses.
Shekhar A; Johnson PL; Fitz SD; Nakazato A; Chaki S; Steckler T; Schmidt M
Int J Neuropsychopharmacol; 2011 Apr; 14(3):355-65. PubMed ID: 21087553
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus.
Shekhar A; Johnson PL; Sajdyk TJ; Fitz SD; Keim SR; Kelley PE; Gehlert DR; DiMicco JA
J Neurosci; 2006 Sep; 26(36):9205-15. PubMed ID: 16957077
[TBL] [Abstract][Full Text] [Related]
13. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats.
Battaglia G; Monn JA; Schoepp DD
Neurosci Lett; 1997 Jul; 229(3):161-4. PubMed ID: 9237483
[TBL] [Abstract][Full Text] [Related]
14. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
Ferris P; Seward E; Dawson GR
J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
[TBL] [Abstract][Full Text] [Related]
15. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats.
Konieczny J; Ossowska K; Wolfarth S; Pilc A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):500-2. PubMed ID: 9826074
[TBL] [Abstract][Full Text] [Related]
16. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors.
Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Mayne NG; Wu S; Cockerman SL; Burnett JP; Belegaje R; Bleakman D; Monn JA
Neuropharmacology; 1997 Jan; 36(1):1-11. PubMed ID: 9144636
[TBL] [Abstract][Full Text] [Related]
17. Neural pathways underlying lactate-induced panic.
Johnson PL; Truitt WA; Fitz SD; Lowry CA; Shekhar A
Neuropsychopharmacology; 2008 Aug; 33(9):2093-107. PubMed ID: 18059441
[TBL] [Abstract][Full Text] [Related]
18. Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results.
Kellner M; Muhtz C; Stark K; Yassouridis A; Arlt J; Wiedemann K
Psychopharmacology (Berl); 2005 Apr; 179(1):310-5. PubMed ID: 15821951
[TBL] [Abstract][Full Text] [Related]
19. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
[TBL] [Abstract][Full Text] [Related]
20. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
Cartmell J; Monn JA; Schoepp DD
J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
